H ow many times have you heard or seen a drug name and said to yourself, "That name certainly sounds or looks like another drug"? A recently reported problem of this type involves Zyrtec and Zyprexa. The names are similar and each agent is available as a 5 and 10 mg tablet. Other easily confused product names (eg, Lamictal, Lamisil, lamivudine, Ludiomil, labetalol, Lomotil) continue to lead to mix-ups and medication errors.
How can we avoid or at least decrease the risk of look-alike/ soundalike drugs becoming medication errors? One way is to be aware of the problem and look for situations that increase the risk of mix-ups, before they occur. Another method is to make sure that look-alike and sound-alike lists or posters are displayed in key pharmacy work areas and nursing stations. Finally, another approach is to report "near misses" to pharmacy, medical, and nursing staff through inservices or newsletters and to the United States Pharmacopeia (USP) Medication Errors Reporting Program, the Institute for Safe Medication Practices (ISMP), or the Food and Drug Administration (FDA).
The first option sounds the easiest but is sometimes the hardest to achieve. In the case of Zyrtec and Zyprexa, some of the errors could have been avoided if the patients knew why they were receiving the drug (and these reasons were confirmed during the patient-counseling encounter) or if the indication was written on the prescription order. Handwritten prescriptions could have been typed or computer-generated. Good telephone communication skills may have prevented sound-like problems from occurring with phoned-in prescriptions.
Displaying lists or posters in the work area is the easiest method, as long as they are used. So what happened to your copy of the poster that was distributed with the November 2001 issue of Hospital Pharmacy? Is it still in the journal, in a file, or on the wall? More of these posters can be purchased from Facts and Comparisons at 800-223-0554. A list of lookalike/sound-alike drug names can also be found in issue 76 of the USP Quality Review (March 2001). A pdf version of the USP list can be found at h t t p : / / w w w. u s p . o r g / r e p o r t i n g / review/qr76.pdf.
Reports submitted to the USP are shared with ISMP, the FDA, and the manufacturer/labeler, if appropriate.
Errors involving drug names can be reported online to the USP Medication Errors
Reporting Program at www.usp.org. After logging on, select the "Practitioner Reporting" link on the left side of the screen. You can also report the error to USP by calling 800-23-ERROR (800-233-7767). If you report the error via the ISMP Web site (www.ismp.org), you will find links to the USP Medication Errors Reporting Program and the MedWatch Online Voluntary Reporting Form. Either link can be used to report the error.
Another option is for manufacturers to take advantage of ISMP's Medical Error Recognition and Revision Strategies or Neil Davis's Safe Medication Practice Consultants. These organizations can screen new drug names for potential problems prior to their entry into the marketplace and thus prevent problems before they happen. ISMP All of these steps are ways to improve the safety of our patients and the quality of their care. If you are a practitioner, help identify new problems with drug names by reporting them to one of the organizations listed above and by distributing or displaying lists or posters of easily confused drug names at various locations in your institution. If you are a manufacturer, please have new drug names screened by one or both of these organizations for potential problems prior to marketing.
